Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

BACKGROUND: Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the potential benefits and potential risks of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Friend, Susan, Richman, Sandra, Bloomgren, Gary, Cristiano, Lynda M., Wenten, Madé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995778/
https://www.ncbi.nlm.nih.gov/pubmed/27552976
http://dx.doi.org/10.1186/s12883-016-0674-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995778/
https://www.ncbi.nlm.nih.gov/pubmed/27552976
http://dx.doi.org/10.1186/s12883-016-0674-4

Ejemplares similares